Opipramol

Opipramol, sold under the brand name Insidon among others, is an anxiolytic and tricyclic antidepressant that is used throughout Europe. Despite chemically being a tricyclic dibenzazepine (iminostilbene) derivative similar to imipramine, opipramol is not a monoamine reuptake inhibitor like most other tricyclic antidepressants, and instead, uniquely among antidepressants, acts primarily as a SIGMAR1 agonist. It was developed by Schindler and Blattner in 1961.

Opipramol
Clinical data
Trade namesInsidon, Pramolan, others
Other namesG-33040; RP-8307
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • BR: Class C1 (Other controlled substances)
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability94%
Protein binding91%
MetabolismCYP2D6-mediated
Elimination half-life6–11 hours
ExcretionUrine (70%), feces (10%)
Identifiers
  • 4-[3-(5H-dibenz[b,f]azepin- 5-yl)propyl]-1-piperazinethanol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.005.687
Chemical and physical data
FormulaC23H29N3O
Molar mass363.505 g·mol−1
3D model (JSmol)
  • OCCN1CCN(CC1)CCCN4c2ccccc2\C=C/c3ccccc34
  • InChI=1S/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2 Y
  • Key:YNZFUWZUGRBMHL-UHFFFAOYSA-N Y
 NY (what is this?)  (verify)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.